



# Eversense<sup>®</sup> CGM System

The world's **FIRST** and **ONLY** long-term Continuous Glucose Monitoring System

---

**Tim Goodnow, PhD**  
President and CEO

Corporate Presentation  
August 2022

---

# FORWARD-LOOKING STATEMENTS

Any statements in this presentation about future expectations, plans and prospects for Senseonics, including statements about patient benefits, perceptions, uptake of the Eversense E3 product, and the ability to introduce the product to additional patients, statements regarding future coverage decisions and final outcomes, statements concerning Senseonics' product pipeline and future product enhancements, and other statements containing the words "believe," "expect," "anticipate", "intend," "may," "projects," "will," "planned," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and projections about future events, and such statements are, by their nature subject to uncertainties.

The risks and uncertainties that may cause actual results, levels of activity, performance or achievements to differ materially from the Company's current expectations include uncertainties related to the commercial launch and commercial expansion of the Eversense product, uncertainties inherent in the transition of commercialization responsibilities to Ascensia Diabetes Care and its commercial initiatives, uncertainties in insurer, regulatory and administrative processes, decisions and policy determinations, the risks attendant to the launch and commercialization of a new product in a competitive market, the availability of capital to fund the Company's continued operations and execute its business plan, and such other factors that are more fully described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission ("SEC") on March 1, 2022, the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as filed with the SEC on August 9, 2022, and its other filings with the SEC. Statements made in this presentation speak only as of the date of this presentation and should not be relied upon as of any subsequent date, and the Company assumes no obligation to update any such forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.




# OUR MISSION

To transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology.



# CORPORATE OVERVIEW AND MILESTONES


The **FIRST** and **ONLY** long-term and implantable CGM System. Available by prescription in US and select markets in Europe. Proven technology with rich development history, regulatory approvals and commercial accomplishments.



NOTE: Items in blue are based on a number of risks and assumptions.

# HIGH GROWTH MARKET

## CGM Fastest Growing Diabetes Technology Segment Globally\*



**\$14B+**  
Annual US  
Market  
Opportunity


\*Estimates for top 4 CGM companies (Dexcom, Abbott, Medtronic and Senseonics), based upon available publicly stated guidance, historic performance, and external CGM market models.

\*Company reports, company and analyst estimates.

# SIGNIFICANT UNMET NEED AMONG BGM/CGM USERS




## Why BGM users won't adopt CGM<sup>1</sup>



## Most desired CGM improvements<sup>2</sup>

- ★ Longer Sensor Wear
- ★ Better Accuracy



<sup>1</sup> Market Segmentation Research June 2019


<sup>2</sup> dQ&A CGM US Patient Survey Q3 2020

dQ&A CGM US Patient Survey Q3 2020

Eversense CGM System addresses **unmet** needs as

# THE **FIRST** AND **ONLY**

- CGM that lasts for 6 months vs. days
- Fully implantable 3rd generation sensor
- CGM achieves 8.5% MARD
- Transmitter that is removable
- System with on-body vibe alerts for hypo and hyper warnings
- System with fresh, gentle-on skin adhesive patch
- Device that does not require self-insertions
- Sensor that is MRI compatible



Therapeutic indication for 18 yo and older.



# EVERSENSE US PATIENT PROFILES<sup>1</sup>

## Broad appeal of Eversense with new and existing CGM users


### Target patient profiles

- Dissatisfied with Current CGM
- New to CGM
- Gateway (Libre)


### Top preferred features of existing users

- Accuracy
- Sensor Life
- Implantable Convenience


Where Eversense users come from



Usage split evenly across age groups



Users by Diabetes Type



<sup>1</sup> Senseonics Analysis



# PROVEN TOP-TIER ACCURACY IN PROMISE STUDY<sup>1</sup>

## MARD: 8.5%

- Prospective multi-center pivotal trial at 8 sites in the US for new 180-day sensor
- 181 T1 and T2 subjects inserted with primary sensor
- Subset (n=43) inserted with secondary sensor with modified (SBA) chemistry

\* MARD (Mean Absolute Relative Difference) is a measure of accuracy. A lower value indicates closer accuracy to reference value.


<sup>1</sup> ATTD Scientific Session Oral Presentation June 3, 2021



Exceptional Performance for Duration of 180 Days


### Accurate and stable for 6 months

Percent of readings within 15 mg/dL or 15% of reference value



### Highly accurate – particularly in low range

Percent of readings within 15 mg/dL or 15% of reference value



# STRONG AND EXPANDING REIMBURSEMENT

- Recent Anthem coverage decision, expands access to over 250 million lives
- Strong adoption of 180-day payment across Commercial payers
- CMS issued G-codes, effective July 1st – providing Medicare beneficiaries access to 180-day product

aetna

EmblemHealth

BlueCross.  
BlueShield.  
Federal Employee Program

Florida  
Blue

Cigna

HCSC  
Health Care Service Corporation

Humana

blue  
california

Blue  
Cross of Idaho

HIGHMARK

Harvard Pilgrim  
Health Care

CareFirst  
BlueCross BlueShield

hmsa  
An Independent Licensee of the Blue Cross and Blue Shield Association

BlueCross  
BlueShield

Horizon  
Horizon NJ Health

TRICARE

U.S. Department  
of Veterans Affairs

AmeriHealth

Excellus

BlueCross  
BlueShield  
Arizona

Independence

Medicare

# COMMERCIAL COLLABORATION WITH ASCENSIA

- Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in BGM
- ASCENSIA is the Exclusive Worldwide Distribution Partner for Eversense®, Eversense® XL, Eversense® E3 and Future Generation Products
- Senseonics to Focus Streamlined Operations on Manufacturing, Research and Development of Next Generations of Eversense® Systems

## Leverage ADC commercial strength with current and new products



- A leader in BGM with 80 YEARS of innovative diabetes care products
- Approximately \$1B in sales in over 125 countries and covering 10 million people
- Approximately 1700 employees working in 31 countries

Eversense CGM (90D in US)  
Eversense XL CGM (180D in OUS)  
Eversense E3 CGM (180D in US, EU)

### Focus Areas:

- Focus in select markets with reimbursement
- Build brand awareness and adoption
- Protect and grow installed base

### NEW

Eversense 180D  
(US and EU)\*

2022 – 2025\*\*

WW Annual Commercial  
Investment:

≈ \$30M to \$80M per year

\* Projected launch

\*\* Current investment and headcount  
plans with ADC. Subject to change.

A woman with curly hair is smiling and stretching her arm in a gym. She is wearing a white tank top and a small black sensor on her upper arm. In the background, another person is visible, also in a gym setting. The entire image is overlaid with a semi-transparent blue filter. The text "EVERSENSE PIPELINE" is centered in white, bold, uppercase letters.

# EVERSENSE PIPELINE



# PRODUCT VISION

Uniquely differentiated long-term technology solution with multiple product configurations

# 1

## SENSOR

All Diabetes Patient Segments

**NO** sensor change for 1 year

**NO** daily calibration required

**NO** transmitter on body

NOTE: Product vision subject to a number of assumptions and regulatory approval.



For Type 1 and Type 2 Patients  
On Demand and Continuous Monitoring

# SENSEONICS PRODUCT PIPELINE

## 2016 - 2022

**Eversense® CGM**  
90-day CGM system

**Eversense® XL CGM**  
180-day CGM system

**Eversense® DMS**  
Cloud-based data management app

**Eversense® DMS Pro**  
Cloud-based HCP data management app

**Eversense® NOW**  
Remote monitoring app

**180D CGM**  
6-month sensor with advanced chemistry and features

**Remote Patient Monitoring and Wellness**  
Integration with Apple health and other third-party diabetes management apps

## 2022 - 2025

**BGM Connectivity**  
Direct communication with Bluetooth enabled blood glucose meters

**Pump Integration**  
Sensor augments pump

**Pump AID**  
CGM controls pump

**365D CGM (Rome)**  
One year sensor for continuous readings, 1 cal/week

**365D CGM (Rome2)**  
One-year sensor with battery for continuous and optional point-in-time reading (Gemini)

**365D FGM (Rome2)**  
One-year sensor for point-in-time reading


T1D/T2D Intensively-Managed

T2D Insulin-Using

T2D Non-Insulin-Using

# EVERSENSE 365 SYSTEM

One annual sensor for use – CGM for peace of mind and FGM for discretion



## TECHNOLOGY

Gen 2 sensor (Rome); array-based sensing

## USE CASE

Full year use with 1 sensor and 1 cal/week

## TARGET


Intensively managed patients who want better control

**+ All insulin-using patients**

NOTE: Timelines and development attributes subject to a number of risks, assumptions and uncertainties.

# FREEDOM SYSTEM

Autonomous sensor testing with data processing capacity enabling 2 products from 1 platform



## TECHNOLOGY

Enhanced Rome 2 sensor with integrated battery; updated algorithm

## USE CASE

Full year use with 1 sensor and 1 cal/week

Two unique products:

1. CGM with transmitter/FGM without transmitter
2. Standalone therapeutic FGM without transmitter

## TARGET

Intensively managed patients who want better control

+ All insulin-using patients

+ Non-insulin patients

NOTE: Timelines and development attributes subject to a number of risks, assumptions and uncertainties.



**eversense**  
Continuous Glucose Monitoring System



**“ACCURATE.  
CONVENIENT.  
LIFE-CHANGING.”**

**eversense**  
Continuous Glucose Monitoring System



**THANK YOU**

